
This article was downloaded by: [Universitaetsbibliothek Giessen]

On: 28 January 2015, At: 11:20 Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered

office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

http://www.tandfonline.com/loi/lcar20

Synthesis of Sialyl Lewis X Analogues

Gyula Dekany $^{\rm a}$, Karen Wright $^{\rm a}$, Peter Ward $^{\rm b}$ & Istvan Toth $^{\rm a}$ $^{\rm a}$ The School of Pharmacy , University of London , 29-39 Brunswick Square , London , WC1N 1AX

^b Glaxo Group Research Ltd., Greenford Road, Greenford, UB6 ORE, UK

Published online: 22 Aug 2006.

To cite this article: Gyula Dekany, Karen Wright, Peter Ward & Istvan Toth (1996) Synthesis of Sialyl Lewis X Analogues, Journal of Carbohydrate Chemistry, 15:4, 383-398, DOI: 10.1080/07328309608005661

To link to this article: http://dx.doi.org/10.1080/07328309608005661

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions

SYNTHESIS OF SIALYL LEWIS X ANALOGUES

Gyula Dekany, Karen Wright, Peter Ward and Istvan Totha.*

^aThe School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, ^bGlaxo Group Research Ltd., Greenford Road, Greenford, UB6 ()HE, UK

Received August 11, 1995 - Final Form January 23, 1996

ABSTRACT

Sialyl Lewis X (SLe^x) analogs **2a** and **2b** were synthesised, where the *N*-acetyl-D-glucose and the D-galactose units of SLe^x 1 were replaced with an alkyl and a heteroalkyl spacer. Sulphate ester **6i** was also synthesised from alcohol **6b** and chlorosulphonic acid. A novel promoter, silver mercaptoethanesulphonate, was used to synthesise α -sialosides **2c**, **7b** and **7c**.

INTRODUCTION

Carbohydrate-mediated cell adhesion is an important event in inflammation initiated by tissue injury or infection and is involved in metastasis. 1.2.3 One of these adhesion processes is the interaction between E-selectin (expressed on the surface of endothelial cells during inflammation) and a glycotope structure displayed on the surface of neutrophils. The ligand recognised by E-selectin was identified as the tetrasaccharide sialyl Lewis X (SLex, 1).2.4 Further studies indicated that the sulphosaccharide Lex 3-O-sulphate was also a ligand of E-selectin.5

A mimetic of SLe^x that inhibits the interaction between E-selectin and SLe^x could be clinically useful as an anti-inflammatory or an anti-metastatic agent.

It has been demonstrated that the carboxylic acid function of the sialic acid moiety and fucose residue of SLe^x are the most significant units for binding to E-selectin.⁴ It was decided that SLe^x analogues, mimicking the natural structure, would be synthesised where the *N*-acetyl-D-glucosamine and galactose units of SLe^x are replaced by an alkyl - $(CH_2)_6$ -and a heteroalkyl - $(CH_2)_2O(CH_2)_3$ - spacer. The spacer moieties in compounds **2a** and **2b**

keep the two essential sugars approximately the same distance apart as in SLex.

To synthesise the analogues **2a** and **2b** our strategy was either to build up the fucose-spacer conjugate **6b** and couple it to a sialic acid residue, or to construct the sialyl-spacer unit **7d** and couple it to the fucose unit.

RESULTS AND DISCUSSION

6-Benzyloxyhexan-1-ol, synthesised by benzylation of 1,6-hexanediol, was a suitable starting compound for the synthesis of SLe^x analogue 2a. For the construction of compound 2b heteroalkyl spacer ethers 5a and 5b were synthesised from the partially benzylated diols 3a and 3b via tosyl derivatives 4a and 4b.

Synthesis of α -fucosides: A stereospecific α -fucosylation method was sought for the synthesis of **6b**. High yields of α -fucosides had been reported using dimethyl(methylthio)sulphonium triflate (DMTST),^{6,7} dimethyl(methylthio)sulphonium tetrafluoroborate (DMTSB),⁸ iodonium dicollidine perchlorate (IDCP),⁹ and iodonium dicollidine trifluoromethanesulfonate (IDCT)¹⁰ as promoters, from thiofucoside donors. Halide ion catalyzed glycosylation was also applied,¹¹ with DMTST and tetraethylammonium bromide (TEAB) used to form bromofucosides *in situ.* 1,2-*cis* specific glycosidation had been achieved through the use of nitrile solvents.^{12,13}

Using these different glycosylation methods, the $\alpha:\beta$ ratio of fucosides **6b:6c** was examined. In each reaction methyl 2,3,4-tri-O-benzyl-1-thio- β -fucopyranoside **6a**^{7,14} was used as glycosyl donor, and the acceptor was either 1,6-hexanediol or compound **5a**. The $\alpha:\beta$ ratio of products was determined by TLC (results summarised in Table 1). The best result was obtained when a mixture of bromofucosides **6d** and **6e** (prepared from **6a** by bromine treatment¹⁵) reacted with 1.6-hexanediol in a halide ion catalysed glycosylation in acetonitrile, ^{12,13} giving **6b** and **6c** as a 9:1 mixture of anomers.

Synthesis of α-sialosides: The glycosylation of simple alcohols with 2-halogeno-Neu5Ac derivatives (halogen=F, Cl, Br) under Koenigs-Knorr reaction conditions has been widely investigated. Primary alcohols reacted with 2-chloro-sialic acid derivatives in the present of insoluble silver salts (e.g., silver carbonate, salycilate, polymaleate) affording α-sialosides. 16,17,18 With less reactive alcohols, having secondary or sterically hindered hydroxyl groups, the main product was the 2,3-dehydro-Neu5Ac derivative formed by intramolecular elimination. The mechanism of this type of surface active promoters is poorly understood. Silver salts of hydroxy carboxylic acids (especially those that can form a 6-member ring structure, like silver salicylate) were more successful promoters than salts such as silver carbonate. 19 It was proposed that a concerted reaction can take place on the surface of these silver salts, leading to stereoselective glycosylation with inversion of configuration. 20

Van der Vleugel et al. 16 employed silver salicylate in the coupling reaction of a chloro-sialic acid derivative and alcohols. In these reactions α -glycosides were isolated stereoselectively in 65% yield (the β -anomers present only in 3% yield) without elimination. Sialosides of salicylic acid can also form in the reaction as reported by Wulff and Wichelhaus. 21

We applied silver salicylate (Ag-sal) promoted glycosylation to prepare compounds 7b and 7c. Compound $7a^{22,23}$ was reacted with 1,6-hexanediol or 5b yielding α -sialosides 7b and 7c but glycosylated salicylic acid derivatives were also formed as major products with the 2,3-dehydro-derivative of sialic acid as a minor by-product.

An attempt was made to overcome this problem by the use of a novel promoter, silver 2-mercaptoethanesulphonate (Ag-MES), easily prepared from silver nitrate and sodium 2-mercaptoethanesulphonate. This promoter should be capable of forming a 6-member ring structure in the same way as silver salicylate. The possibility of

Table 1. Summary of the glycosylation reactions (D=donor, A=acceptor, hd=1,6-hexanediol)

6.7 datio cutio cm ratio cm rat	Ref	D	Α	D:A	D:A Solvent	Temp	Temp Promotor system	α:B
6a hd 1.2:1 CH ₂ Cl ₂ Vbenzene 25 6a hd 1.2:1 CH ₂ Cl ₂ DMF 25 6a hd 1:2 CH ₂ Cl ₂ DMF 25 6a hd 1:2:1 benzene 25 6a hd 1:2:1 benzene 25 6a hd 1:1.7 CH ₂ Cl ₂ cther 25 6a hd 1:1.7 CH ₂ Cl ₂ cther 25 6a hd 1:2.5 CH ₃ CN -15 6d,6e hd 1:5 CH ₃ CN -15 6d,6e hd 1:5 CH ₃ CN -15				ratio		J _o	(mol eq)	99:q9
6a hd 1.2:1 CH ₂ Cl ₂ 25 6a hd 1:2 CH ₂ Cl ₂ DMF 25 6a hd 1:2:1 benzene 25 6a hd 1:1:1 L2-dimethoxyethane 25 6a hd 1:1:1 CH ₂ Cl ₃ cther 25 6a hd 1:1:7 CH ₂ Cl ₃ cther 25 6a hd 1:2:5 CH ₃ CN -15 6d,6e hd 1:5:5 CH ₃ CN -15	6,7	6a	рч	1.2:1	CH ₂ Cl ₂ /benzene	25	DMTST (3)	1:1
6a hd 1:2 CH ₂ Cl ₂ DMF 25 6a hd 1:2 (CH ₂) ₂ Cl ₂ DMF 25 6a 7b 1.2:1 benzene 25 6a hd 1:1 1,2-dimethoxyethane 25 6a hd 1:1.7 CH ₂ Cl ₃ ether 25 6a hd 1:1.7 CH ₃ CN -15 6a,6 hd 1:2.5 CH ₃ CN -15 6a,6 hd 1:5 CH ₃ CN -15	9	6a	þq	1.2:1	CH ₂ Cl ₂	25	DMTST/TEAB (3:5)	3:7
6a hd 1:2 CH ₂) ₂ Cl ₂ DMF 25 6a 7b 1.2:1 benzene 25 6a hd 1:1 L'-dimethoxyethane 25 6a hd 1:1.7 CH ₂ Cl ₃ cther 25 6a hd 1:2.5 CH ₃ CN -15 6d,6e hd 1:5 CH ₃ CN -15	9	6a	рq	1:2	CH ₂ Cl ₂	25	DMTST/TEAB (1:5)	4:6
6a 7b 1.2:1 benzene 25 6a hd 1:1 1,2-dimethoxyethane 25 6a hd 1:1.7 CH ₂ Cl ₂ ether 25 6a 5a 1:2.5 CH ₃ CN -15 6a,6e hd 1:2.5 CH ₃ CN -15 6d,6e hd 1:2.5 CH ₃ CN -15 6j,6k hd 1:5 CH ₃ CN 25	9	6a	þq	1:2	(CH ₂) ₂ Cl ₂ /DMF	25	DMTST/TEAB (0.9:5)	8:2
6a hd 1:1 1,2-dimethoxyethane 25 6a hd 1:1.7 CH ₂ Cl ₃ ether 25 6a 5a 1:2.5 CH ₃ CN -15 6a,6 hd 1:2.5 CH ₃ CN -15 6d,6 hd 1:2.5 CH ₃ CN -15 6j,6k hd 1:5 CH ₃ CN 25	9	6a	7b	1.2:1	benzene	25	DMTST (1.4)	2:1**
6a hd 1:1.7 CH ₂ Cl ₃ ether 25 6a 5a 1:2.5 CH ₃ CN -15 6a hd 1:2.5 CH ₃ CN -15 6d,6e hd 1:2.5 CH ₂ CN -15 6d,6e hd 1:5 CH ₂ Cl ₂ 25 6j,6k hd 1:5 CH ₃ CN 25	×	6a	þq	Ξ	1,2-dimethoxyethane	25	DMTSB (1.5)	3:5
1:2.5 CH ₃ CN -15 1:2.5 CH ₃ CN -15 1:2.5 CH ₃ CN -15 1:5 CH ₂ Cl ₂ 25	9,10	6a	걸	1:1.7		25	IDCT (2)	4:6
1:2.5 CH ₃ CN -15 1:2.5 CH ₃ CN -15 1:5 CH ₂ Cl ₂ 25	13	6a	5a	1:2.5	CH,CN	-15	DMTST/s-collidine (1.2:1)	1:1*
1:2.5 CH ₃ CN -15 15 15 15 15 15 15 15 15 15 15 15 15 1	13	6a	þq	1:2.5	CH3CN	-15	DMTST (1.2)	1:1
1.5 CH ₂ Cl ₂ 25 7 1.5 CH ₃ CN 25 7	12	6d,6e	pq	1:2.5		-15	AgOTf (1.5)	1:1
1:5 CH ₃ CN 25	=	6d,6e	pq	1:5	CH ₂ Cl ₂	25	TEAB (5)	7:3
	=	6j,6k	þq	1:5	CH3CN	25	TEAB (5)	9:1

*61:6m, "2c:8

D	A	D:A ratio	Product	Solvent	Promoter	α/β ratio	Yield %
7a	hd	1:10	7b	benzene	Ag-MES	1:0	70
7a	hd	1:10	7 b	benzene	Ag-sal	1:0	60
7e	hd	1:3	7b	MeCN	DMTST	1:1	80
7a	6b	1:1	2c	benzene	Ag-sal	1:0	30
7a	6b	1;1	2c	benzene	Ag-MES	1:0	5 0
7a	5 b	2;9	7c	benzene	Ag-sal	1:0	55
7a	5b	2:9	7c	benzene	Ag-MES	1:0	75

Table 2. Summary of the sialylation reactions (D=donor, A=acceptor, hd=1,6-hexanediol)

glycosylation of the promoter was reduced by the replacement of the carboxylic acid function with a sulphonic acid group. Glycosylation *via* the mercapto group is unlikely to occur with silver salt promotion.

¹H NMR examination of reaction mixtures in comparative glycosylations with silver 2-mercaptoethanesulphonate and silver salicylate showed that silver 2-mercaptoethanesulphonate promotion gave the α-sialosides 7b and 7c in higher yield than silver salicylate, with the 2,3-dehydro-Neu5Ac derivative as a minor product. No glycosides of the promoter or β-sialylation were observed. A comparative nitrilium-nitrile glycosylation of 1,6-hexanediol was also carried out using the methylthiosialoside donor 7e, with DMTST promotion at -15 °C. While this method gave a high yield of sialoside, both α and β anomers were formed. Results of the sialylation reactions are summarised in Table 2.


The deprotection of the side chain of 7c was carried out by Pd-charcoal assisted hydrogenation, resulting in alcohol 7d.

Synthesis of SLe^x analogues: For the synthesis of compound 2a, the 9:1 mixture of 6b and 6c was separated by flash chromatography and α -fucoside 6b was reacted with glycosyl chloride 7a in the presence of silver 2-mercaptoethanesulphonate, yielding α -sialoside 2c. The deprotection of compound 2c was carried out by hydrogenation (Pd/C),


Zemplen deprotection (NaOMe) and aqueous/base hydrolysis to give the SLe^x analogue 2a.

When sialoside 7b was reacted with fucosyl bromides 6d and 6e in a bromide ion promoted glycosylation, an inseparable mixture of compounds 2c and 8c was formed. A similar reaction of sialoside 7d with 6d and 6e resulted in an inseparable anomeric mixture of 2d and 8d. Catalytic hydrogenation of the mixture of 2d and 8d yielded compounds 2e and 8e which were again inseparable. Zemplen deprotection followed by base hydrolysis of 2e and 8e resulted in compounds 2b and 8b, which were separated by flash chromatography.


Synthesis of sulphate ester 6i: Alcohol 6b was reacted with chlorosulfonic acid, yielding compound 6h, which was deprotected by catalytic hydrogenation resulting in analogue 6i.



6	R^{1}	R^2	\mathbb{R}^3
a	Н	SCH ₃	Bzl
b	$O(CH_2)_6OH$	Н	Bzl
c	Н	O(CH ₂) ₆ OH	Bzl
d	Br	Н	Bzl
e	Н	Br	Bzl
f	$O(CH_2)_2O(CH_2)_3OBzl$	Н	Bzl
g	Н	$O(CH_2)_2O(CH_2)_3OBzl$	Bzl
h	O(CH ₂) ₆ OSO ₃ H	Н	Bzl
i	O(CH ₂) ₆ OSO ₃ H	Н	Н



7	R^1	\mathbb{R}^2	\mathbb{R}^3
a	Cl	Ac	COOCH ₃
b	COOCH ₃	Ac	O(CH ₂) ₆ OH
c	COOCH ₃	Ac	O(CH ₂) ₃ O(CH ₂) ₂ OBzI
đ	COOCH,	Ac	$O(CH_2)_3O(CH_2)_2OH$
e	COOCH ₃	Ac	SCH ₃



2,8	\mathbb{R}^1	R^2	\mathbb{R}^3	spacer
a	COOH	Н	Н	(CH ₂) ₆
b	COOH	Н	Н	$(CH_2)_3O(CH_2)_2$
c	COOCH ₃	Ac	Bzl	$(CH_2)_6$
đ	COOCH ₃	Ac	Bzl	$(CH_2)_3O(CH_2)_2$
e	COOCH ₃	Ac	Н	(CH ₂) ₃ O(CH ₂) ₂

3. 4 n

a 2

b 3

4

$$CE_{2}-O-(CE_{2})_{n}-OE$$

5 n m

a 3 2

b 2 3

$$CE_{2}-O-(CE_{2})_{n}-OE$$

$$CE_{2}-O-(CE_{2})_{n}-OE$$

$$CE_{2}-O-(CE_{2})_{n}-OE$$

5 \(CE_{2}-O-(CE_{2})_{n}-OE

EXPERIMENTAL

Purification was achieved by flash chromatography on Sorbsil C60-H40/60, using mobile phases as stated. Reaction progress was monitored by thin layer chromatography on Kieselgel 60 F₂₅₄ using mobile phases as stated. Solvents were evaporated under reduced pressure with a rotary evaporator. ¹H NMR spectra were obtained with a Bruker AM 500 instrument operating at a field of 500 MHz. Chemical shifts are reported in ppm downfield from internal TMS. Mass spectra were run with a VG Analytical ZAB-SE instrument using fast atom bombardment (FAB) techniques -20 kV Cs⁺ ion bombardment, with 2 μL of appropriate matrix, either 3-nitrobenzyl alcohol or thioglycerol with NaI (MeOH) solution added when necessary to produce natriated species when no protonated molecular ions were observed. The anomeric configuration of sialosides was determined by the use of empirical rules for acetyl protected sialoside when both anomers were present.²⁴ When only one anomer was isolated the configuration was determined by comparing H-3eq, H-4 and J₇₈ with typical values for α and β sialosides.^{25,26}

Silver 2-mercaptoethanesulphonate Sodium 2-mercaptoethanesulphonate was dissolved (1.0 g, 6.09 mmol) in THF - H₂O 5:2 v/v (7 mL) and silver nitrate (0.83 g, 4.87 mmol) in THF -H₂O 1:1 v/v (6 mL) was added dropwise at 40 °C, then the mixture was stirred for 30 minutes. The reaction mixture was cooled to room temperature and filtered.

The solid was washed with THF (30 mL) and ether 50 (mL), then dried over P_2O_5 giving the product as a yellow solid (1.1 g, 91 %).

2-Benzyloxyethyl *p*-toluenesulphonate (4a), 2-Benzyloxyethan-1-ol (3a) (9.57 g, 62.9 mmol) and 4-dimethylaminopyridine (96 mg, 0.78 mmol) were dissolved in pyridine (125 mL), cooled to 0 °C, and *p*-toluenesulfonyl chloride (16.73 g, 88.1 mmol) was added. The mixture was stirred for 3 hours and concentrated. The residue was taken up in ether (250 mL) and washed with water (50 mL), then with 1N HCl (50 mL) and with saturated NaHCO₃ solution (50 mL). The organic phase was dried over MgSO₄ and concentrated. The residue was purified by chromatography using hexane/EtOAc 3:1 v/v, to give 4a (11.29 g, 81 %): R₁ 0.55 (hexane/EtOAc 3:1 v/v): ¹H NMR (CDCl₃) δ 7.73-7.72 (dd, 2H, Ar-H), 7.22-7.18 (m, 7H, Ar-H), 4.41 (s, 2H, CH₂Ar), 4.13 (dd, 2H, CH₂O), 3.59 (t, 2H, CH₂O), 2.36 (s, 3H, CH₃); FAB MS C₁₆H₁₈O₄S (306.36) *m/z* (%) 329 [M+Na]⁺ (51), 307 [M+H]⁺ (7), 199 (8), 155 (5), 107 (8), 91 (100).

3-Benzyloxypropyl *p*-toluenesulphonate (4b). 3-Benzyloxypropan-1-ol (3b) (8.4 g, 50.6 mmol) was dissolved in pyridine (110 mL), and 4-dimethylaminopyridine (84 mg, 0.68 mmol) was added. The mixture was cooled to 0° C, then *p*-toluenesulfonyl chloride (12.52 g, 65.7 mmol) was added, and the mixture was stirred for 3 hours. The mixture was concentrated, and the residue was taken up in ether (350 mL). The undissolved solid was filtered off, and the filtrate washed with water (50 mL), 1N HCl (50 mL), saturated NaHCO₃ (50 mL) and with water (50 mL) again. The organic phase was dried over MgSO₄ and concentrated. The residue was purified by chromatography using hexane/EtOAc 3:1 v/v, to give 4b (12.9 g, 80 %): R₁ 0.40 (hexane/EtOAc 3:1 v/v); ¹H NMR (CDCl₃) δ 7.78 (d, 2H, 2 ArH), 7.39-7.22 (m, 7H, 7 ArH), 4.42 (s, 2H, CH₂Ar), 4.19 (t, 2H, CH₂O), 3.50 (t, 2H, CH₂O), 2.42 (s, 3H, CH₃), 1.94 (m, 2H, CH₂); FAB MS C₁₇H₂₀O₄S (320.38) *m/z* (%) 343 [M+Na]⁺ (38), 321 [M+H]⁺ (9), 213 (8), 155 (8), 107 (9), 91 (100).

2-(3-Benzyloxypropoxy)ethanol (5a). A mixture of 4b (670 mg, 2.09 mmol), ethylene glycol (590 mg, 9.44 mmol), potassium hydroxide (262 mg, 4.7 mmol), and xylene (0.5 mL) was stirred at 130-140 °C for 3 hours. The mixture was allowed to cool, and benzene (6 mL) and water (3 mL) were added. The organic phase was separated, dried over MgSO₄, filtered and concentrated. The residue was purified by chromatography using hexane/EtOAc 1:1 v/v as the mobile phase, to give 5a (316 mg,

72.0 %): R_f 0.4 (hexane/EtOAc 1:1 v/v): ¹H NMR (CDCl₃) δ 7.30-7.18 (m, 5H, 5 ArH), 4.45 (s, 2H, CH₂Ar), 3.63 (t, 2H, CH₂O), 3.55-3.50 (m, 4H, 2 CH₂O), 3.45 (t, 2H, CH₂O), 2.40 (bs, 1H, OH), 1.83 (m, 2H, CH₂): FAB MS $C_{12}H_{18}O_3$ (210.26) m/z (%) 211 [M+H]⁺ (53), 149 (15), 107 (12), 103 (16), 91 (100).

3-(2-Benzyloxyethoxy)propanol (**5b**). A mixture of **4a** (3.0 g, 9.8 mmol). 1,3-propanediol (3.3 g, 44.2 mmol), potassium hydroxide (1.2 g, 22.0 mmol) and xylene (2.2 mL) were heated at 130-140 °C for 5 hours. Benzene (26 mL) and water (12 mL) were added. The water phase was extracted with benzene (2x10 mL) and the benzene phase was washed with water (2x3 mL). The collected benzene phases were dried over MgSO₄ and concentrated. The residue was purified by chromatography using EtOAc/hexane 2:1 v/v, to give **5b** (1.42 g, 68.9 %): R_f 0.3 (EtOAc/hexane 2:1 v/v); ¹H NMR (CDCl₃) δ 7.29-7.16 (m, 5H, 5 ArH), 4.44 (s, 2H, CH₂Ar), 3.76, 3.65, 3.52, 3.45 (4t, 8H, 4 CH₂O), 2.68 (bs, 1H, OH), 1.85 (m, 2H, CH₂): FAB MS C₁₂H₁₈O₃ (210.26) m/z (%) 233 [M+Na]⁺ (74), 211 [M+H]⁺ (15), 91 (100).

6-Hvdroxyhexvl 2,3,4-tri-O-benzyl- α and -B-L-fucopyranoside (6b) and (6c). Compound 6a (0.7 g, 1.50 mmol) was dissolved in dichloromethane (10 mL) and bromine (260 mg, 1.60 mmol) added, and the mixture stirred for 5 minutes. Cyclohexene was added until the bromine colour disappeared. The solvent was evaporated and the residue was taken up in MeCN (20 mL). Molecular sieves 4A (5.0 g), TEAB (1.6 g, 7.5 mmol), and 1,6-hexanediol (0.9 g, 7.5 mmol) were added and the mixture stirred for 3 days. The reaction mixture was diluted with MeCN (20 mL) and filtered. The filtrate was concentrated and the residue was taken up in CH2Cl2 (20 mL) and washed with NaCO3 solution (2 mL), and water (2 mL). The organic phase was dried over MgSO4, and concentrated. The crude product was purified by chromatography using hexane/ether/methanol 7:10:1 v/v/v as the mobile phase, to give **6b** (α-fucoside) (690 mg, 86.2 %): R_f 0.30 (hexane/ether/methanol 7:10:1 v/v/v); ¹H NMR (CDCl₃) δ 7.41-7.26 (m, 15H. 15 ArH), 4.96, 4.87, 4.81, 4.74, 4.68, 4.65 (6d, 6H, 3 CH₂Ar), 4.78 (d, 1H, H-1, $J_{1,2}$ =3.66 Hz), 4.02 (dd, 1H, H-2), 3.93 (dd, 1H, H-3), 3.70 (m, 1H, H-5), 3.65 (d, 1H, H-4), 3.61 (t, 2H, CH₂O), 3.59 (m, 1H, CH₂Oa), 3.43 (m, 1H, CH₂Ob), 1.63 (m, 2H, CH₂), 1.62 (bs, 1H, OH), 1.55 (m, 2H, CH₂), 1.40-1.35 (m, 4H, 2 CH₂), 1.10 (d, 3H, H-6); FAB MS $C_{33}H_{42}O_6$ (534.67) m/z (%) 557 [M+Na]⁺ (62), 181 (14), and **6c** (β -fucoside) (48 mg, 6.0 %): R_1 0.27 (hexane/ether/methanol 7:10:1 v/v/v); H NMR (CDCl₃) δ 7.37-7.26 (m,

15H, 15 ArH), 4.98-4.68 (6d, 6H, 3 CH₂Ar), 4.30 (d, 1H, H-1, $J_{1,2}$ =7.6 Hz), 3.79 (t, 1H, H-2), 3.54 (d, 1H, H-4), 1.66-1.30 (m, 8H, 4 CH₂), 1.16 (d, 3H, H-6); FAB MS $C_{34}H_{42}O_6$ (534.67) m/z (%) 557 [M+Na]⁺ (60), 181 (15).

6-Hydroxyhexyl 2,3,4-tri-*O*-benzyl-α-L-fucopyranoside 6-hydrogensulfate (6h). Pyridine (12 mL) was cooled to O °C and chlorosulfonic acid (770 mg, 6.64 mmol) and compound **6b** (355 mg, 0.66 mmol) were added. The reaction mixture was stirred at O °C for 3 hours then dry methanol (1 mL) was added. The reaction mixture was concentrated. The crude product was purified by chromatography twice using EtOAc/methanol 10:3 v/v, then CH₂Cl₂/methanol 10:2 v/v later as the mobile phases, to give **6h** (325 mg, 79.6 %): ¹H NMR (CDCl₃) δ 7.39-7.24 (m, 15H, 15 ArH), 4.37-4.61 (6d, 6H, 3 CH₂Ar), 4.77 (d, 1H, H-1, J_{1,2}=3.0 Hz), 4.10 (t, 2H, CH₂O), 4.02 (dd, 1H, H-2), 3.96 (dd, 1H, H-3), 3.90 (m, 1H, H-5), 3.69 (d, 1H, H-4), 3.58 (m, 1H, CH₂Oa), 3.40 (m, 1H, CH₂Ob), 1.77-1.22 (m, 8H, 4 CH₂), 1.11 (d, 3H, H-6); FAB MS C₃₃H₄₂O₉S (614.76) m/z (%) 659 [M+Na]⁺ (45), 371 (43), 307 (35), 165 (87), 91 (100).

6-Hydroxyhexyl α-L-fucopyranoside 6-hydrogensulfate (6i). Compound 6h (90 mg, 0.14 mmol) was dissolved in acetic acid (4 mL), and Pd/C (10%) (50 mg) was added. The reaction mixture was stirred under hydrogen for a day. The catalyst was filtered off and the filtrate was concentrated. The crude product was purified by chromatography using EtOAc/methanol/water 10:5:2 v/v/v as the mobile phase, to give 6i (23 mg, 74.9%): R_f 0.51 (EtOAc/methanol/water 10:5:2 v/v/v); ¹H NMR (CDCl₃) δ 4.72 (d, 1H, H-1, $J_{1,2}$ = 3.88 Hz), 3.92 (t, 2H, CH₂O), 3.70 (dd, 1H, H-2), 3.65 (d, 1H, H-4), 3.61 (dd, 1H, H-3), 3.54 (m, 1H, CH₂Oa), 3.38 (m, 1H, CH₂Ob), 1.60-1.25 (m, 8H, 4 CH₂), 1.07 (d, 3H, H-6): FAB MS C₁₂H₂₄O₉S (212.26) m/z (%) 257 [M+2Na]⁺ (32).

Methyl (6-hydroxyhexyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranoside)onate (7b). A mixture of 7a (130 mg, 0.25 mmol), 1,6-hexanediol (300 mg, 2.5 mmol) and silver 2-mercaptoethanesulphonate (92 mg, 0.37 mmol) in benzene (1 mL) was stirred for 4 days. Benzene (10 mL) was added, the mixture was filtered, and the residue rinsed with benzene (5 mL). The combined filtrate was washed with water (3 mL), saturated NaHCO₃ solution (3 mL), and with water (3 mL) again. The combined aqueous phases were extracted with benzene (20 mL). The combined organic phases were dried over MgSO₄ and concentrated. The residue was purified by chromatography using EtOAc/methanol 10:0.7 v/v, to give 7b (103 mg, 69.8)

%): R_t 0.30 (EtOAc/methanol 10:0.5 v/v); ¹H NMR (CDCl₃) δ 5.39 (m. 1H, H-8), 5.32 (dd, 1H, H-7, $J_{7.8}$ =8.46 Hz), 5.17 (d, 1H, NH), 4.84 (m, 1H, H-4), 4.34 (dd, 1H, H-9'), 4.14-4.05 (m, 3H, H-5, H-6, H-9), 3.79 (s, 3H, CH₃), 3.75 (m, 1H, CH₂Oa), 3.64 (t, 2H, CH₂O), 3.26-3.21 (m, 1H, CH₂Ob), 2.58 (dd, 1H, H-3_{eq}), 1.94 (t, 1H, H-3_{ax}), 2.19, 2.04, 2.01, 1.89 (4s, 15H, 4 AcO, NAc), 1.66-1.55 (m, 4H, 2 CH₂), 1.42-1.35 (m, 4H, 2 CH₂); FAB MS $C_{26}H_{41}NO_{14}$ (591.59) m/z (%) 614 [M+Na]⁺ (100), 414 (27).

Methyl [3-(2-benzyloxyethoxy)propyl 5-acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranoside]onate (7c). A mixture of 7a (370 mg, 0.72 mmol), 5b (676 mg, 3.22 mmol) and silver 2-mercaptoethanesulphonate (392 mg. 1.58 mmol) in benzene (6 mL) was stirred for 3 days. The mixture was filtered, and the filtrate was concentrated. The residue was taken up in chloroform (20 mL) and washed with saturated NaHCO₃ solution (4 mL) and water (4 mL), dried over MgSO₄, and concentrated. The residue was purified by chromatography using hexane/ether/methanol 7:7:2.5 v/v/v, to give 7c (370 mg, 74.6 %): R₁ 0.55 (hexane/ether/methanol 7:7:2.5 v/v/v); ¹H NMR (CDCl₃) δ 7.35-7.26 (m, 5H, 5 ArH), 5.38 (m, 1H, H-8), 5.31 (dd, 1H, H-7), 5.14 (d, 1H, NH), 4.83 (m, 1H, H-4), 4.56 (s, 2H, CH₂Ar), 4.30 (dd, 1H, H-9'), 4.11-4.03 (m, 3H, H-5, H-6, H-9), 3.79 (m, 1H, CH₂Oa), 3.76 (s, 3H, CH₃O), 3.52 (m, 2H, CH₂O), 3.34 (m, 1H, CH₂Ob), 2.57 (dd, 1H, H-3_{eq}, J_{4,3}=4.5 Hz), 2.13, 2.12, 2.02, 2.01, 1.87 (5s, 15H.4 OAc, NAc), 1.93 (t, 1H, H-3_{ax}, J_{4,3}=12.5 Hz), 1.84 (m, 2H, CH₂). FAB MS C₃₂H₄₅NO₁₅ (683.74) m/z (%) 706[M+Na]⁺ (95), 624 (5), 413 (30), 91 (27).

Methyl [(3-hydroxyethoxy)propyl 5-acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranoside]onate (7d). Compound 7c (175 mg, 0.25 mmol) was dissolved in methanol (5 mL) and Pd/C (10%) catalyst (100 mg) was added. The mixture was stirred under hydrogen for 3 days, then filtered. The filtrate was concentrated and the residue was purified by chromatography using hexane/ether/methanol 4:7:3 v/v/v as the mobile phase, to give 7d (143 mg, 94.0 %): R_f 0.47 (hexane/ether/methanol 4:7:3 v/v/v): ¹H NMR (CDCl₃) δ 5.42 (m, 1H, H-8), 5.31 (dd, 1H, H-7), 5.12 (d, 1H, NH), 4.83 (m, 1H, H-4), 4.30 (dd, 1H, H-9'), 4.12-4.05 (m, 3H, H-5, H-6, H-9), 3.87 (m, 1H, CH₂Oa), 3.80 (s, 3H, OCH₃), 3.72 (m, 2H, CH₂O), 3.57-3.35 (m, 4H, 2 CH₂O), 3.35 (m, 1H, CH₂Ob) 2.57 (dd, 1H, H-3_{eq}), 2.15, 2.14, 2.04, 2.02, 1.88 (5s, 4 0Ac, NAc), 1.94 (t, 1H, H-3_{ax}), 1.82 (m, 2H, CH₂): FAB MS C₂₅H₃₉NO₁₅ (593.58) *m/z* (%) 616 [M+Na]⁺ (32).

Methyl [6-(2,3,4-tri-O-benzyl-α-L-fucopyranosyloxy)-1-hexyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranoside]onate (2c). A mixture of 7a (116 mg, 0.227 mmol), 6b (120 mg, 0.224 mmol) and silver 2mercaptoethanesulphonate (99 mg, 0.40 mmol) in benzene (1.2 mL) was stirred at room temperature for 24 hours. Benzene (15 mL) was added and the mixture was filtered. The filtrate was washed with saturated NaHCO3 solution (2.5 mL) and water (2.5 mL). The organic phase was dried over MgSO₄, filtered and concentrated. The residue was purified by chromatography using hexane/ether/methanol 7:7:2.5 v/v/v as the mobile phase, to give 2c (112 mg, 49.8 %): R_t 0.40 (hexane/ether/methanol 7:7:2.5 v/v/v): ¹H NMR (CDCl₃) δ 7.41-7.26 (m, 15H, 15 Ar-H), 5.41 (m, 1H, H- 8_{sia}), 5.33 (dd, 1H, H- 7_{sia}), 5.12 (d, 1H, NH), 4.90-4.64 (m, 6H, 3 CH₂Ar), 4.85 (m, 1H, H- 4_{sia}), 4.81 (d, 1H, H- 1_{fix} , $J_{1,2}$ =3.6 Hz), 4.32 (dd. 1H, H-9'_{sia}), 4.14-4.07 (m, 3H, H-5_{sia}, H-6_{sia}, H-9_{sia}), 4.03 (dd. 1H, H-2_{fuc}), 3.94 (dd, 1H, H- 3_{fuc}), 3.87 (m, 1H, CH₂Od), 3.79 (s, 3H, OCH₃), 3.70 (m, 1H, H- 5_{fuc}), 3.67 (d, 1H, H-4_{fuc}), 3.61 (m. 1H, CH₂Ob), 3.43 (m. 1H, CH₂Oc), 3.23 (m. 1H, CH₂Oa), 2.58 (dd, 1H, H-3_{eusia}), 2.15, 2.14, 2.03, 2.01, 1.88 (5s, 15H, 4 OAc, NAc), 1.95 (t, 1H, H-3_{avsia}), 1.62-1.27 (m, 8H, 4 CH₂), 1.11 (d, 3H, H- 6_{10c}); FAB MS $C_{53}H_{69}NO_{18}$ (1008.84) m/z (%) 1031 [M+Na]⁺ (5), 1008 (10), 948 (20), 620 (10), 591 (10), 532 (10), 474 (15), 414 (68), 91 (100).

Methyl [6-(2,3,4-tri-*O*-benzyl-α and -β-I.-fucopyranosyloxy)hexyl 5-acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranoside]onate (2c) and (8c). Compound 6a (39 mg, 0.081 mmol) in CH₂Cl₂ (6 mL) was stirred at room temperature and bromine (15.6 mg, 0.096 mmol) in CH₂Cl₂ (1 mL) was added. The mixture was stirred for 5 minutes. Cyclohexene was added until the bromine colour disappeared. The solvent was evaporated and the residue was taken up in MeCN (6 mL). Molecular sieves 4A (300 mg), TEAB (96 mg, 0.45 mmol), and 7b (48 mg, 0.081 mmol) were added and the mixture stirred for 3 days. The reaction mixture was diluted with acetonitrile (10 mL) and filtered. The filtrate was concentrated and the residue was taken up in CH₂Cl₂ (15 mL) and washed with saturated NaHCO₃ solution (3 mL) and water (3 mL). The organic phase was dried over MgSO₄, filtered, and concentrated. The crude product was purified by chromatography using hexane/ether/methanol 7:7:2.5 v/v/v as the mobile phase, to give a mixture of 2c and 8c (30 mg, 41.9 %): R₁ 0.35 (hexane/ether/methanol 7:7:2.5 v/v/v/): ¹H NMR (CDCl₃) δ 7.38-7.25 (m, 15H, 15 Ar-H).

5.38 (m, 1H, H-8_{sia}), 5.31 (dd, 1H, H-7_{sia}), 5.13 (d, 1H, NH), 4.98-4.65 (m, 6H, 3 CH₂Ar), 4.75 (m, 1H, H-4_{sia}), 4.29 (dd, 1H, H-9_{sia}), 3.77 (s, 3H, OCH₃), 3.54 (dd, 1H, H-4_{fic}), 3.51 (dd, 1H, H-3_{fic}), 3.44 (m, 1H, H-5_{fic}), 2.57 (m, 1H, H-3_{eq,sia}), 2.13, 2.12, 2.02, 2.01, 1.87 (5s, 15H, 4 OAc, NAc), 1.93 (t, 1H, H-3_{ax,sia}), 1.64-1.33 (m, 8H, 4 CH₂), 1.18, 1.12 (2d, 3H, H-6_{fic}); FAB MS m/z (%) C₅₃H₆₉NO₁₈ (1008.84) 1031 [M+Na]⁺ (7), 1008 (12), 948 (23), 620 (12), 591 (13), 532 (14), 474 (18), 414 (70), 91 (100).

6-(α-L-Fucopyranosyloxy)hexyl 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-**2-nonulopyranoside** (**2a**). Compound **2c** (30 mg, 0.03 mmol) was dissolved in methanol (5 mL) and was hydrogenated over Pd/C (10 %) (30 mg) catalyst for 3 days. The mixture was filtered and sodium methoxide (20 mg, 0.26 mmol) was added. The reaction mixture was stirred at room temperature for 24 hours. Water (0.5 mL) was added, and the mixture was stirred at 40 °C for 12 hours. The mixture was neutralised with Amberlite IR-120 (H⁺) ion exchange resin and filtered. The filtrate was concentrated, and then lyophilised to give **2a** (17 mg, 96 %): R_f 0.45 (chloroform/methanol/water 5:6:2 v/v/v); ¹H NMR (D₂O) δ 4.72 (d, 1H, H-1_{fuc}, J_{1.2}=3.86 Hz), 4.61 (s, 7H, OH), 3.91 (m, 1H, CH₂Oa), 3.73-3.30 (m, 14H, 11 OH, 3 CH₂O_{b.c.d}), 2.60 (dd, 1H, H-3_{eq.sia}, J_{4.3}=4.75 Hz), 1.89 (s, 3H, NAc), 1.82 (s, 1H, H-3_{ax.sia}), 1.46 (m, 4H, 2 CH₂), 1.22 (m, 4H, 2 CH₂), 1.07 (d, 3H, H-6_{fuc}); FAB MS C₂₃H₄₁NO₁₄ (555.58) m/z (%) 600 [M+Na]⁺ (20).

Methyl $\{3-[2-(2,3,4-tri-O-benzyl-\alpha \text{ and } -\beta-1-fucopyranosyloxy}\}$ propyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2nonulopyranoside onate (2d) and (8d). Thioglycoside 6a (123 mg, 0.26 mmol) was dissolved in dry CH₂Cl₂ (5 mL) and bromine (45.7 mg, 0.28 mmol) in CH₂Cl₂ (2 mL) was added. The mixture was stirred at room temperature for 5 minutes and cyclohexene (0.5 mL) was added then the colourless solution was concentrated. The residue was taken up in dry MeCN (5 mL), and tetraethylammonium bromide (273 mg, 1.3 mmol), compound 7d (143 mg, 0.14 mmol) and molecular sieves 4Å (1.0 g) were added. The reaction mixture was stirred at room temperature for 2 days. The mixture was diluted with CH₂Cl₂ (40 mL) and the solids present were filtered off. The filtrate was extracted with saturated NaHCO₃ solution (3 mL) and water (3 mL). The organic phase was dried over MgSO₄ concentrated. residue was purified by chromatography hexane/ether/methanol 4:7:2 v/v/v as the mobile phase, to give the mixture of 2d and 8d (170 mg, 69.9 %): R_f 0.45 (hexane/ether/methanol 4:7:2 v/v/v): ¹H NMR (CDCl₃) δ 7.387.23 (m, 15H, 15 Ar-H), 5.32 (m, 1H, H-8_{sia}), 5.31 (dd, 1H, H-7_{sia}), 5.15 (d, 1H, NH), 4.85 (d, 1H, H-1_{fuca}), 4.83 (m, 1H, H-4_{sia}), 4.37, 4.84, 4.79, 4.73, 4.68, 4.64 (6d, 6H, 3 CH₂Ar), 4.36 (d, 1H, H-1_{fucβ}), 4.30 (dd, 1H, H-9'_{sia}), 4.14-4.06 (m, 3H, H-5_{sia}, H-6_{sia}, H-9_{sia}), 4.08 (dd, 1H, H-2_{fuc}), 3.35 (dd, 1H, H-5_{fuc}), 3.78 (m, 1H, CH₂Oa), 3.76 (s, 3H, OCH₃), 3.72 (m, 1H, CH₂Ob), 3.65 (d, 1H, H-4_{fuc}), 3.64-3.44 (m, 5H, CH₂Oc, 2 CH₂O), 3.33 (m, 1H, CH₂Od), 2.56 (dd, 1H, H-3_{eq,sia}), 2.13, 2.11, 2.02, 2.01 (4s, 12H, 4 0Ac), 1.92 (t, 1H, H-3_{ax,sia}), 1.79 (m, 2H, CH₂), 1.16, 1.10 (2d, 3H, H-6_{fuca,β}), α/β ratio = 70/30; FAB MS C₅₂H₆₅NO₁₉ (1010.10) m/z (%) 1032 [M+Na]* (100), 91 (65).

Methyl {[3-(2-α and -β-L-fucopyranosyloxy)ethoxy]propyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranoside}onate (2e) and (8e). Mixture of 2d and 8d (165 mg, 0.16 mmol) was dissolved in methanol (5 mL) and Pd/C (10%) (50 mg) was added. The mixture was stirred under hydrogen for 3 days. The catalyst was filtered off, and the filtrate was concentrated. The residue was purified by flash chromatography. using ether/methanol 10:3 v/v as the mobile phase, to give the mixture of 2e and 8e (110 mg, 91.6 %): R_f 0.38 (ether/methanol 10:3 v/v); ¹H NMR (CDCl₃) δ 5.37 (m. 1H. H-8_{sia}), 5.31 (m. 2H. H-7_{sia}, NH), 4.89, 4.25 (2d. 1H. H-1_{fucu}, H-1_{fucβ}), 4.84 (m. 1H. H-4_{sia}), 4.34 (dd. 1H. H-9'_{sia}), 4.13-4.02 (m. 3H. H-5_{sia}, H-9_{sia}), 3.79 (s, 3H, OCH₃), 3.37 (m. 1H, CH₂Oa), 2.57 (dd. 1H, H-3_{eqsia}), 2.13, 2.03, 2.01, 1.87 (4s, 15H, 4 OAc, NAc), 1.92 (t, 1H, H-3_{ax,sia}), 1.82 (m, 2H, CH₂), 1.32, 1.28 (2d, 3H, H-6_{fucβ,α}); FAB MS $C_{31}H_{49}NO_{19}$ (739.73) m/z (%) 762 [M+Na]⁺ (100).

3-[2-(α-L-Fucopyranosyloxy)ethoxy]propyl 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranoside (2b). A mixture of 2e and 8e (80 mg, 0.01 mmol) and sodium methoxide (30 mg, 0.05 mmol) was dissolved in dry methanol (6.5 mL) and stirred at room temperature for 24 hours. Water (1 mL) was added and the reaction mixture stirred at 40 °C for 10 hours. The reaction mixture was diluted with water (10 mL) and the methanol was evaporated. The water solution was neutralized with Amberlite IR-120 (H⁺), and filtered. The filtrate was lyophilised. The residue was purified by chromatography using chloroform/methanol/water 10:10:3 v/v/v as the mobile phase, to give the product 2b (30 mg, 50 %): R_f 0.35 (chloroform/methanol/water 10:10:3 v/v/v); ¹H NMR (D₂O) δ 4.73 (d, 1H, H-1_{huc}, J_{1,2}=4.O Hz), 3.95 (m, 1H, CH₂Oa), 3.75-3.48 (m, sugar protons, 4 CH₂O), 2.58 (dd, 1H, H-3_{eq,sia}), 1.88 (s, 3H, NAc), 1.72 (m, 2H, CH₂), 1.56 (t, 1H, H-3_{ax,sia}), 1.07 (d, 3H, H-6_{fuc}): FAB MS C₂₂H₁₉NO₁₅ (557.55) m/z (%) 602 [M+2Na]₊ (38), 329 (37), 286 (56).

ACKNOWLEDGMENT

This work was supported by a Glaxo GroupResearch Ltd. grant (No. S-363). The authors wish to thank Mr. M. Zloh and Mr. M. Cocksedge for their assistance in obtaining NMR and mass spectra.

REFERENCES

- 1. T. Springer, *Nature (London)*, **346**, 425 (1990).
- M. Phillips, E. Nudelman, F. Gaeta, M. Perez, A. Singhal, S-I. Hakomori and J.Paulson, Science, 250, 1130 (1990).
- T. Springer and L. Lasky, Nature (London), 349, 196 (1991).
- 4. a) M. Tiemeyer, S. Sweidler, M. Ishihara, M. Moreland, H. Schweingruber, P. Hirtzer and B. Brandley, *Proc. Natl. Acad. Sci. U.S.A.*, **88**, 1138 (1991); b) A. Hasegawa, M. Yoshida, A. Uchimura, and M. Kiso, *Glycoconjugate J.*, **10**, 3 (1993).
- 5. C-T. Yuen, A. M. Lawson, W. Chai, M. Larkin, M. S. Stoll, A. C. Stuart, F. X. Sullivan, T. J. Aherm and T. Feizi, *Biochemistry*, 31, 9126 (1992).
- F. Andersson, P. Fugedi, P. Garegg, and M. Nashed, Tetrahedron Lett., 27, 3919 (1986).
- 7. A. Kaneyama, H. Ishida, M. Kiso and A. Hasegawa, J. Carbohydr. Chem., 10, 549 (1991).
- 8. L. Blomberg and T. Norberg, *J. Carbohydr. Chem.*, **11**, 751 (1992).
- 9. G. Veeneman and J. Van Boom, Tetrahedron Lett., 31, 275 (1990).
- G. Veeneman, S. Van Leeuwen, H. Zuurmond and J. Van Boom, J. Carbohydr. Chem., 9, 783 (1990).
- 11. R. Lemieux, K. Hendricks, R. Stick and K. James, J. Am. Chem. Soc., 97, 4056 (1974).
- 12. R. Schmidt and E. Rucker, *Tetrahedron Lett.*, **21**, 1421 (1980).
- 13. R. Schmidt, M. Behrendt and A. Toepfer, Synlett, 694 (1990).
- H. A. Nunez, J. V. O'Connor, P. A. Rosevear and R. Barker, Can. J. Chem., 59, 2086 (1981).
- 15. B. Luning, T. Norberg and J. Tejbrant, J. Carbohydr. Chem., 11, 933 (1992).
- D. Van der Vleugel, W. Van Heeswijk and J. Vliegenthart, Carbohydr. Res., 102, 121 (1982).
- 17. P. Meindl and H. Tuppy, *Monatsh. Chem.* **96**, 802 (1965).
- 18. V. Eschenfelder and R. Brossmer, Carbohydr. Res. 78, 190 (1980).
- 19. G. Wulff and G. Röhle, Angew. Chem. Int. Ed. Engl., 13, 157 (1974).
- 20. G. Wulff, G. Röhle and W. Kruger, Angew. Chem. Int. Ed. Engl., 9, 455 (1970).
- 21. G. Wulff and J. Wichelhaus, *Chem. Ber.* **112**, 2847 (1979).
- 22. A. Marra and P. Sinay, *Carbohydr. Res.*, **190**, 317 (1989).
- 23. R. Kuhn, P. Lutz and D. MacDonald, Chem. Ber., 99, 611 (1966).
- 24. K. Okamoto and T. Goto, *Tetrahedron*, **46**, 5835 (1990).
- 25. O. Kanie, M. Kiso and A. Hasegawa, J. Carbohydr. Chem., 7, 501 (1988).
- J. Haverkamp, H. Van Halbeek, L. Dorland, J. Vliegenthart, E. Pfeil and R. Schauer, Eur. J. Biochem., 122, 305 (1982).